| ID Source | ID |
|---|---|
| PubMed CID | 25096 |
| CHEMBL ID | 1200467 |
| SCHEMBL ID | 41333 |
| MeSH ID | M0331416 |
| Synonym |
|---|
| hydroxyzine pamoate |
| smr000058728 |
| KBIO1_000503 |
| DIVK1C_000503 |
| SPECTRUM5_000838 |
| SPECTRUM_000911 |
| BSPBIO_002166 |
| hyydroxyzine pamoate |
| IDI1_000503 |
| 10246-75-0 |
| atarax-p (tn) |
| D01096 |
| vistaril pamoate (tn) |
| hydroxyzine pamoate (jp17/usp) |
| NCGC00094698-02 |
| NCGC00094698-01 |
| 2-(2-(4-(p-chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)ethanol 4,4'-methylenebis(3-hydroxy-2-naphthoate) (1:1) |
| atarax p |
| masmoran |
| (+-)-2-(2-(4-(p-chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)ethanol 4,4'-methylenebis(3-hydroxy-2-naphthoate) (1:1) |
| hydroxyzine embonate |
| paxisitil |
| einecs 233-582-1 |
| bobsule |
| equipose |
| MLS000028605 , |
| KBIO2_006527 |
| KBIOSS_001391 |
| KBIO3_001386 |
| KBIO2_001391 |
| KBIOGR_000385 |
| KBIO2_003959 |
| SPECTRUM3_000463 |
| SPECTRUM4_000013 |
| SPECTRUM2_001000 |
| SPBIO_001099 |
| NINDS_000503 |
| SPECTRUM1500345 |
| HMS2091L19 |
| CHEMBL1200467 |
| nsc-757063 |
| HMS501J05 |
| HMS1920F11 |
| NCGC00021152-03 |
| NCGC00021152-02 |
| pharmakon1600-01500345 |
| nsc757063 |
| HMS2235O19 |
| CCG-40218 |
| hy-pam |
| nsc 757063 |
| hydroxyzine pamoate [usp:jan] |
| unii-m20215mufr |
| m20215mufr , |
| sr-01000003149 |
| SR-01000003149-4 |
| hydroxyzine pamoate salt |
| AKOS015914218 |
| S5649 |
| hydroxyzine pamoate [vandf] |
| hydroxyzine pamoate [jan] |
| hydroxyzine pamoate [orange book] |
| hydroxyzine pamoate [usp monograph] |
| (+/-)-2-(2-(4-(p-chloro-.alpha.-phenylbenzyl)-1-piperazinyl)ethoxy)ethanol 4,4'-methylenebis(3-hydroxy-2-naphthoate) (1:1) |
| hydroxyzine embonate [mart.] |
| hydroxyzine embonate [who-dd] |
| hydroxyzine pamoate [usp-rs] |
| hydroxyzine pamoate [mi] |
| SCHEMBL41333 |
| HY-B0895 |
| hydroxyzine (pamoate) |
| FT-0697190 |
| J-000695 |
| hydroxyzine pamoate, united states pharmacopeia (usp) reference standard |
| hydroxyzine pamoate salt, analytical standard |
| mfcd00058051 |
| SR-01000003149-2 |
| SBI-0051413.P003 |
| F15112 |
| 2-(2-(4-((4-chlorophenyl)(phenyl)methyl)piperazin-1-yl)ethoxy)ethan-1-ol 4,4'-methylenebis(3-hydroxy-2-naphthoate) |
| Q27114645 |
| 6-ethylthiomorpholin-3-one |
| HMS3886G14 |
| MS-31366 |
| DTXSID00907580 |
| Class | Description |
|---|---|
| piperazinium salt | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 41.4299 | 0.0447 | 17.8581 | 100.0000 | AID485294; AID485341 |
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 16.7761 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 19.9526 | 0.0251 | 20.2376 | 39.8107 | AID893 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 19.9526 | 0.0251 | 20.2376 | 39.8107 | AID893 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 79.4328 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 50.1187 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 16.5311 | 0.0020 | 14.6779 | 39.8107 | AID1476 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 37.9330 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 5.6234 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 79.4328 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 25.1189 | 0.0126 | 10.6917 | 88.5700 | AID887 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 48.5318 | 0.1413 | 37.9142 | 100.0000 | AID1490; AID2701 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 35.4813 | 0.0316 | 37.5844 | 354.8130 | AID743255 |
| GLS protein | Homo sapiens (human) | Potency | 3.5481 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
| TDP1 protein | Homo sapiens (human) | Potency | 24.1514 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 15.9541 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 56.2341 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
| hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | Homo sapiens (human) | Potency | 7.9433 | 0.0013 | 7.7625 | 44.6684 | AID914; AID915 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 0.3162 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
| 67.9K protein | Vaccinia virus | Potency | 0.3162 | 0.0001 | 8.4406 | 100.0000 | AID720580 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 79.4328 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 50.1187 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 79.4328 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 28.1838 | 0.1337 | 25.4129 | 89.1251 | AID588795 |
| ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 5.0119 | 0.6561 | 9.4520 | 25.1189 | AID927 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 11.9173 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 17.7828 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 79.4328 | 0.1000 | 28.9256 | 213.3130 | AID588591 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 19.9526 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 55.5278 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 19.9526 | 0.0316 | 10.2792 | 39.8107 | AID884; AID885 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 19.9526 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) | Potency | 19.9526 | 6.3096 | 60.2008 | 112.2020 | AID720709 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 19.9526 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 19.9526 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 19.9526 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 19.9526 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 19.9526 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 19.9526 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 19.9526 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 19.9526 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 19.9526 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 19.9526 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 19.9526 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 19.9526 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 19.9526 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | Potency | 5.0119 | 1.5849 | 13.0043 | 25.1189 | AID927 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 19.9526 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 19.9526 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| envelope glycoprotein | Human immunodeficiency virus 1 | IC50 (µMol) | 6.3100 | 2.2000 | 14.8200 | 82.2000 | AID1986 |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | IC50 (µMol) | 1.2303 | 0.1047 | 2.7195 | 7.0795 | AID977603 |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | Ki | 0.9400 | 0.0800 | 2.4688 | 9.8000 | AID977604 |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | IC50 (µMol) | 0.8128 | 0.0500 | 2.3797 | 9.7000 | AID977600 |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | Ki | 0.4500 | 0.0440 | 1.3630 | 5.0000 | AID977601 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID977602 | Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID977604 | Ki values for sodium fluorescein (10 uM) uptake in OATP1B3-transfected CHO cells | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID977603 | pIC50 values for sodium fluorescein (10 uM) uptake in OATP1B3-transfected CHO cells | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID977599 | Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID977600 | pIC50 values for sodium fluorescein (10 uM) uptake in OATP1B1-transfected CHO cells | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID977601 | Ki values for sodium fluorescein (10 uM) uptake in OATP1B1-transfected CHO cells | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID1159550 | Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening | 2015 | Nature cell biology, Nov, Volume: 17, Issue:11 | 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (87.77) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (11.11%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (88.89%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||